Related Funds
Fund Name | Location |
British Business Bank Investments | England, Sheffield, United Kingdom |
Broidy Capital Management | California, Los Angeles, United States |
Devon Park BioVentures | Pennsylvania, United States, Wayne |
East Japan Railway | Chiyoda, Japan |
Hero Enterprise | Delhi, India, New Delhi |
Highgear Capital | China, Guangdong, Shenzhen |
Hills Advertising | - |
Huazhong Touzi | China, Shanghai |
InfraPartners Management | England, London, United Kingdom |
Mark Ventures | Argentina, Buenos Aires, Distrito Federal |
Meriken Nominees | - |
Nutty Capital Venture | China, Hong Kong, Hong Kong Island |
Palm Eco-Town Development Co.,Ltd. | China, Guangdong Province, Panyu District |
SAFA | - |
Target Accelerator | Bangalore, India, Karnataka |
Tokyu Fudosan | Japan, Minato |
Weifang Chuangtou | China, Japan, Kagoshima Prefecture |
Xingyuan Hudong | China, Ningbo, Zhejiang |
Zhongli Hecai Capital | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Xinhengrui Medical | $15M | 17 Jul 2023 | Minhang, Shanghai, China | ||
Affinity | 06 Jul 2023 | Pudong, Shandong, China | |||
Yineng Pharma | $15M | 30 Mar 2023 | Hunan, Hunan, China | ||
Enochic | $7M | 05 Jan 2023 | Shanghai, Shanghai, China | ||
Hechen Biology | 01 Dec 2022 | Hefei, Anhui, China | |||
Hechen Biology | 01 Sep 2022 | Hefei, Anhui, China | |||
Juncell Therapeutics | 15 Jan 2022 | Jiading, Shanghai, China | |||
Mobile Vision Network Technology | 17 Nov 2021 | Shanghai, Shanghai, China | |||
Leads Biolabs | $100M | 08 Oct 2021 | Nanjing, Jiangsu, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Xinhengrui Medical | $15M | 17 Jul 2023 | Minhang, Shanghai, China | ||
Affinity | 06 Jul 2023 | Pudong, Shandong, China | |||
Yineng Pharma | $15M | 30 Mar 2023 | Hunan, Hunan, China | ||
Enochic | $7M | 05 Jan 2023 | Shanghai, Shanghai, China | ||
Hechen Biology | 01 Dec 2022 | Hefei, Anhui, China | |||
Hechen Biology | 01 Sep 2022 | Hefei, Anhui, China | |||
Juncell Therapeutics | 15 Jan 2022 | Jiading, Shanghai, China | |||
Mobile Vision Network Technology | 17 Nov 2021 | Shanghai, Shanghai, China | |||
Leads Biolabs | $100M | 08 Oct 2021 | Nanjing, Jiangsu, China |